Clinical Trials Logo

Lung Diseases clinical trials

View clinical trials related to Lung Diseases.

Filter by:

NCT ID: NCT06297096 Not yet recruiting - Systemic Sclerosis Clinical Trials

Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease

NINTOC-TU
Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

The study includes adult patients with systemic sclerosis (SSc) with interstitial lung disease (ILD) to evaluate the efficacy and safety of nintedanib plus tocilizumab combination therapy compared to standard therapy (methotrexate, mycophenolate mofetil) for 56 weeks.

NCT ID: NCT06290245 Recruiting - Clinical trials for Pulmonary Disease, Chronic Obstructive

PEP Buddy Impact on Breathing, Exercise, and Sleep Quality in COPD Patients

Start date: March 2024
Phase: N/A
Study type: Interventional

Exercise intolerance and sleeping problems are among the most common symptoms experienced by patients with chronic obstructive pulmonary disease (COPD), which is associated with lung dynamic hyperinflation (DH). There was evidence that positive expiratory pressure (PEP), which less costly devices could offer, could reduce DH. A positive expiratory pressure device improved COPD-related symptoms in more than 70% of patients with COPD. PEP buddy is an adjunct to current COPD therapies, such as inhalers and pulmonary rehabilitation. It provides a tool for self-management and breathing re-training, reducing dyspnea and improving quality of life.

NCT ID: NCT06287476 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Alveolar-capillary Reserve After Exercise in Chronic Obstructive Pulmonary Disease (COPD) (COP-DTPA)

Start date: March 15, 2024
Phase: N/A
Study type: Interventional

It is unknown whether individuals with COPD exhibit abnormal alveolar-capillary breaching during exercise, and whether this contributes to exertional dyspnoea. The aim of this study is to investigate whether individuals with COPD exhibit an abnormal increase in alveolar-capillary breaching during exertion, as indicated by an increase alveolar-capillary permeability with a concomitantly exacerbated increase in lung tissue mass.

NCT ID: NCT06286319 Not yet recruiting - Lung Diseases Clinical Trials

Cold Oxygen Lung Preservation and Ventilation With the "Angel Cooler"

Start date: April 2024
Phase: N/A
Study type: Interventional

The objective of this feasibility study is to evaluate continuous temperature monitoring, oxygen (O2) concentration and ventilation with positive end expiratory pressure (PEEP) to keep lungs cooled at 4-8 degrees Celsius, with continuous O2 concentration of 100% and inflated with a PEEP of 8-10 during the entire cold ischemic period.

NCT ID: NCT06283966 Recruiting - Clinical trials for COPD (Chronic Obstructive Pulmonary Disease)

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

THARROS
Start date: February 21, 2024
Phase: Phase 3
Study type: Interventional

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

NCT ID: NCT06280443 Recruiting - Asthma Clinical Trials

Sarcopenia in Chronic Lung Diseases

Start date: November 25, 2022
Phase:
Study type: Observational

Inclusion criteria A)Outpatients with COPD (chronic obstructive pulmonary disease) or ILD (interstitial lung disease) from department of Chest medicine in Taichung Veterans General Hospital, judged by the doctor that they do not need hospitalization or emergent treatment. B) Patients who agree to provide the ID card number to the research team for usage as a link to the National Health Insurance research database and Health bank to explore the continuity of care and the use of medical resources

NCT ID: NCT06275230 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Establishment of Human Lung Stem Cell Proliferation System and Organoid Construction in COPD

Start date: March 20, 2024
Phase:
Study type: Observational

The goal of this study is to proliferate human lung stem cell in vitro in order to establish a lung organoid derived from patients with COPD. The main question it aims to answer are: - Can human lung stem cell proliferate in vitro. - Can a lung organoid derived from patients with COPD be established. Participants will be sampled during pulmonary bronchoscope for organoid establishment.

NCT ID: NCT06272370 Recruiting - Asthma Clinical Trials

Individualizing Treatment for Asthma in Primary Care

iTREAT-PC
Start date: February 1, 2024
Phase: Phase 4
Study type: Interventional

This is a patient level randomized trial for teenagers and adults with asthma who will be randomized to four arms - enhance usual care, rescue inhaled corticosteroids, azithromycin and both rescue inhaled corticosteroids and azithromycin. Participants in all arms will be offered access to an online asthma symptom monitoring system.

NCT ID: NCT06269029 Active, not recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease Moderate

Chest Mobility Exercises Versus Proprioceptive Neuromuscular Facilitation in Patients With COPD

Start date: February 17, 2024
Phase: N/A
Study type: Interventional

Chest mobility exercise versus proprioceptive neuromuscular facilitation in patients with chronic obstructive pulmonary disease

NCT ID: NCT06266442 Recruiting - Clinical trials for Respiratory Tract Diseases

M. Avium WGS During Mav-PD Treatment

Start date: May 13, 2024
Phase:
Study type: Observational

This is a prospective observational study using whole genome sequencing (WGS) to investigate whether new strains (other than the initially identified strain(s)) of M. avium are responsible for persistently culture positive sputum during treatment (refractory disease), or the reversion to culture positive sputum after prior conversion to negative. The study will further investigate for differences between participants living in the Toronto/York region versus participants living elsewhere. The primary goal of this prospective observational study is to understand why some patients with M. avium lung disease have persistent or recurrent M. avium in their sputum despite treatment. The aim is to understand whether it is usually due to treatment failure or new infection.